(Q33947160)

30 July 2017

1 reference

title

Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

Farrell G

1

1 reference

30 July 2017

publication date

1 July 2000

1 reference

Journal of Medical Virology

30 July 2017

published in

1 reference

30 July 2017

volume

61

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

374-379

1 reference

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Natural history of chronic hepatitis B virus infection: an immunopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Interferon in the management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

The management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C374%3A%3AAID-JMV16%3E3.0.CO%3B2-7

10.1002/1096-9071(200007)61:3<374::AID-JMV16>3.0.CO;2-7

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference